LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline - LBPH News | RalliesLB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline
L
LBPH• NOVA-2 topline data timing moved up
- LB Pharmaceuticals posted a press release accelerating expected topline timing for Phase 3 NOVA-2 data for LB-102 in schizophrenia to H1 2027.
- Pre-NDA meeting with the FDA now targeted for H2 2027.
- NOVA-2 plans to enroll about 460 patients across 25 U.S. sites.
•
